PUBLIC COMPANY
save$NVAXNOVAVAX INC
$NVAX7.8900-0.75%Gaithersburg, MD, USupdated 17h ago
Novavax, Inc., based in Gaithersburg, Maryland, develops vaccines to counter infectious diseases. The company developed the Novavax COVID-19 vaccine, now commercialized by Sanofi. The company also develops vaccines for influenza, respiratory syncytial virus (RSV), avian flu, shingles, Clostridioides difficile, and malaria.
community read0 votes
pipeline
4
marketed
1
phase 3
3
catalysts ytd
1
approvals ytd
0
recalls ytd
0
Pipeline(4)
pipeline depth4 products
3Phase 31Marketed
Marketed
Coronavirus Disease 2019 (COVID-19) vaccine 1
Coronavirus Disease 2019 (COVID-19)
Phase 3(Coronavirus disease 2019 (COVID-19) + influenza (trivalent)) vaccine
Coronavirus Disease 2019 (COVID-19)
Phase 3COVID/Influenza Combination Vaccine
Seasonal Influenza
Phase 3influenza (trivalent) vaccine
Seasonal Influenza
Upcoming
Recent(90d)
nothing in the last 90 days
view all catalysts →Insider activity
source: SEC Form 4routine RSU / option mechanics (6)
- Apr 14, 26grantWalker Robert Edward · EVP, R&D66,000 sh
- Apr 14, 26grantWalker Robert Edward · EVP, R&D99,500 sh
- Mar 10, 26option exerciseShiver John W. · 7,947 sh
- Mar 10, 26option exerciseShiver John W. · 7,947 sh
- Mar 7, 26tax coverKelly James Patrick · EVP, CFO and Treasurer5,904 sh
- Mar 7, 26option exerciseKelly James Patrick · EVP, CFO and Treasurer12,223 sh
🐶 Hiring Signal
next earnings Nov 5, 2026
News
no news has mentioned this company yet
Data sources
last refreshed 19m ago
Found something off?
comments(0)
5-min edit window · permanent after that